Dimension Capital’s $800M third fund shows the intersection of science and compute is booming
Dimension Capital has raised an $800 million third fund to invest in startups operating at the intersection of biotechnology and software. The firm has seen rapid growth, backing high-profile AI and drug discovery companies like Chai Discovery and Anthropic.
Why it matters
The success of this fund underscores the growing investor appetite for 'deep-tech' companies that leverage AI to accelerate scientific research and development.
While many newer VC firms are still struggling to raise fresh capital, Dimension Capital, founded in late 2022, has been raising increasingly larger funds in quick succession. On Tuesday, the New York firm — which invests at the intersection of science and compute — announced an $800 million fund, which is 60% larger than its $500 million second vehicle announced just 18 months ago.
When Zavian Dar and Adam Goulburn — formerly partners at Lux Capital —teamed up with Obvious Ventures alum Nan Li to launch the firm four years ago, they bet that founders would increasingly want to build deep-tech companies that crossed the boundaries of biotech and software. Now, the three partners admit to being impressed by how quickly their thesis has played out.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in